Cytokinetics, Incorporated · South San Francisco, CA United States ·(NASDAQ (GM): CYTK)

Cytokinetics studies the cytoskeleton to get to the heart of the problem. The biopharmaceutical firm's development pipeline includes a lead drug candidate -- in oral and intravenous formulations -- designed for the treatment of heart failure based on a cytoskeletal protein in the heart muscle. It is being developed in collaboration with Amgen. Several other candidates are targeting multiple types of cancer; early clinical trials of these anti-cancer candidates were supported by GlaxoSmithKline and the National Cancer Institute. Cytokinetics is responsible for additional clinical development but may seek future strategic alliances to help advance this set of drugs into later-stage trials. To read the full description, subscribe now.

• Amgen Inc.
• Neurocrine Biosciences, Inc.
• PDL BioPharma, Inc.